Patient Search

This trial uses fluid measurements of the arm and MRI to determine biomarkers of lymphatic dysfunction in patients with breast cancer. Studying the lymphatic system (the part of your body that helps to process and clear waste products) in different ways will help doctors understand more about lymphedema (excess fluid after lymph nodes are removed) and help with prevention and management of lymphedema in patients with breast cancer.

This trial studies how well infrared autofluorescence via PTeye works in detecting parathyroid glands during total thyroid surgery. Located closely to the thyroid gland are the parathyroid glands, which are important organs that regulate calcium levels in the body. Thus, it is essential for a surgeon to correctly identify this structure when performing a thyroid surgery. PTeye may help surgeon to identify and preserve healthy parathyroid glands during surgery. By assisting the surgeon in correctly identifying parathyroid glands, this device may improve the quality of the operation performed on the patient.

This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter,
study for patients with neuroblastoma in remission. In this study subjects will receive 730
Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 250 mg/m2 BID (strata 1,
2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on
the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to
prevent recurrence.

The purpose of this study is to create a patient registry in order to assess treatment
patterns, physician reported clinical outcomes and patient-reported health-related quality of
life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel
therapy in the past 6 months and whose treatment is ongoing at the time of enrollment.

This trial collects data on response to low-dose skin electron therapy in patients with stage IB-IIIA mycosis fungoides that does not respond to treatment (refractory) or has come back (relapsed). Collecting data on patient's response to therapy, both in terms of changes in the skin and in terms of quality of life following treatment, may help doctors better predict response to therapy.